Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
Conditions: Ovarian Mucinous Cystadenocarcinoma; Ovarian Mucinous Cystadenoma With Proliferating Activity; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Stage IA Fallopian Tube Cancer; Stage IA Ovarian Epithelial Cancer; Stage IB Fallopian Tube Cancer; Stage IB Ovarian Epithelial Cancer; Stage IC Fallopian Tube Cancer; Stage IC Ovarian Epithelial Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial CancerInterventions: Other: quality-of-life assessment; Drug: carboplatin; Drug: paclitaxel; Drug: oxaliplatin; Drug: capecitabine; Biological: bevacizumabSponsor: National Cancer Institute (NCI)Suspended - verified June 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Cystadenoma | Eloxatin | Epithelial Cancer | Fallopian Tube Cancer | Mucinous Ovarian Cancer | Ovarian Cancer | Ovaries | Research | Xeloda